NCT05660655View on ClinicalTrials.gov

Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Baricitinib 4 MG Oral Tablet

baricitinib 4 mg once daily

DRUG

Baricitinib 2 MG

baricitinib 4mg once daily in group A

Trial Locations (1)

1207

Dr. Md. Sadikul islam, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER